Star Update Podcast - Cardiology News Summaries

Position of Beta-blockers in the Treatment of Hypertension Today: An Indian Consensus

J Assoc Physicians India . 2024 Oct;72(10):83-90. doi:

Abstract

Background: Management of essential hypertension

 Methodology: An expert review panel was constituted,

 Results: Ninety-six percent of respondents opined

Conclusion: Beta-blockers, including metoprolol and nebivolol, can be considered initial-line therapy for Hypertension management in real-life

Disclaimer:

Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this

Short-Term Dual Antiplatelet Therapy

JAMA Cardiol. Published online October 9, 2024.

Abstract

Importance  : The optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) remains under debate.

 Objectives:   To analyze the efficacy and safety of dual antiplatelet therapy strategies in patients with acute coronary syndromes using a bayesian network meta-analysis.

 Data Sources : MEDLINE, Embase, Cochrane, and LILACS databases were searched from inception to April 8, 2024.

 Study Selection :  Randomized clinical trials (RCTs) comparing dual antiplatelet therapy duration strategies

 Data Extraction and Synthesis: This systematic review

 Main Outcomes and Measures :  The primary efficacy end point was major adverse cardiac and cerebrovascular events (MACCE); the primary safety end point was major bleeding.

 Results:  A total of 15 RCTs randomizing 35 ,326 

 Conclusion and Relevance:  Results of this systematic review and network meta-analysis reveal that, in patients with acute coronary syndromes undergoing percutaneous coronary intervention with DES, 1 month of dual antiplatelet therapy followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing major adverse cardiac and cerebrovascular events when compared with 12 months of dual antiplatelet therapy. However, an

Disclaimer:

Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any

Antihypertensive therapy in patients with arterial hypertension and concomitant diseases in real clinical practice (according to the National Registry of Arterial Hypertension, 2019–2022)

https://doi.org/10.26442/00403660.2024.09.202848

Abstract

Background. Arterial hypertension remains the

 Aim. Analyze the real ongoing antihypertensive

 Materials and methods. An analysis was carried out of

 Results. The greatest increase in the number of antihypertensive drugs  was observed in patients with

 Conclusion. The described features of prescribing antihypertensive drugs partially reproduce clinical recommendations for the management of Arterial

Role of ticagrelor in the peri-thrombolytic phase for patients with ST-segment elevation myocardial

Thromb J . 2024 Oct 11;22(1):90. doi: 10.1186/s12959-024-00658-9

Abstract

Recent years have seen ticagrelor, a potent P2Y12 inhibitor, emerge as a significant advancement in the peri-thrombolytic management of patients with ST-segment elevation myocardial infarction (STEMI), offering a promising alternative to traditional antiplatelet drugs like clopidogrel. This review critically examines the efficacy and safety of ticagrelor during the

Disclaimer:

Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any

Pulmonary Vein Isolation vs Sham Intervention in Symptomatic Atrial Fibrillation: The SHAM-PVI Randomized Clinical Trial

JAMA 2024 Sep 2:e2417921. doi: 10.1001/jama.2024.17921

 Abstract

Importance: There are concerns that pulmonary vein isolation for atrial fibrillation may have a profound placebo effect, but no double-blind randomized clinical trials have been conducted.

 Objective: To determine whether pulmonary vein isolation is more effective than a sham procedure for improving outcomes in atrial fibrillation.

 Design, setting, and participants:

Intervention: Participants were randomly assigned to receive pulmonary vein isolation with cryoablation (n = 64) or a sham procedure with phrenic nerve pacing (n = 62).

 Main outcomes and measures: The primary end point was atrial fibrillation burden at 6 months, excluding a

 Results: A total of 126 participants were randomized (mean age, 66.8 years; 89 men [70.63%]; 20.63% with paroxysmal atrial fibrillation). The absolute mean atrial fibrillation burden change from baseline to 6 months

 Conclusions and relevance: Pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation burden at 6 months, with substantial improvements in symptoms and quality of life, compared with a sham procedure.

Disclaimer:

Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any

2024 European Society of Cardiology  Guidelines for Management of Chronic Coronary Syndromes: Key Points

European Heart Journal, ehae177, https://doi.org/10.1093/eurheartj/ehae177

 The key points to remember from the 2024

 · The term chronic coronary syndromes describes

· Managing individuals with suspected CCS involves

The first step is a general clinical evaluation that focuses on assessing symptoms and signs of chronic

· The inclusion of risk factors to classic pretest

· First-line diagnostic testing of suspected CCS

· Coronary computed tomography angiography (CCTA)

· Invasive coronary angiography is recommended to

· A single antiplatelet agent, aspirin or clopidogrel, is generally recommended long term in CCS patients with

· Among CCS patients with normal LV function and

· Among patients with complex multivessel CAD

· Lifestyle and risk factor modification combined

2024 European Society of Cardiology  Guidelines for Management of Elevated BP and Hypertension: Key Points

European Heart Journal, ehae178, https://doi.org/10.1093/eurheartj/ehae178

The key points to remember from the 2024

· The most important point is that the target

· Blood Pressure  is defined as having a continued risk rooted in time of exposure to higher Blood Pressure. For this reason, hypertension is defined as an systolic BP (SBP) >140 mm Hg or diastolic BP (DBP) >90 mm Hg, but a new category of “elevated BP” has been introduced that is an office systolic BP of 120-139 mm Hg or diastolic BP 70-89 mm Hg. This guideline recognizes that risk increases across this scale, rather than starts at a certain level that is defined as “hypertension.” This category of “elevated BP” reminds us of the term “prehypertension” used in JNC-7 (Seventh Report of

· The guideline focuses on true risk reduction

· Out-of-office BP is recommended for diagnostic

· Lifestyle interventions are recommended for 3

· In pregnant women without contraindications and

· A risk-based approach to hypertension treatment

· Screening for secondary hypertension is recommended for adults diagnosed with hypertension before the age of 40 years, except for obese young adults for whom screening for sleep apnea should be a first step.

· Self-measurement of BP is recognized to improve

· It is recognized that the major weakness of

· In patients with atrial fibrillation, manual BPs

·  The guidelines include sex and gender throughout

Disclaimer:

Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any

Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation

DOI: 10.1056/NEJMoa2314328

 Background

Whether transcatheter mitral-valve repair

 Methods

We conducted a randomized, controlled trial

 Results

A total of 505 patients underwent randomization: 250 were assigned to the device group and 255 to the control group. At 24 months, the rate of first or recurrent hospitalization for heart failure or cardiovascular death was 37.0 events per 100 patient-years in the device group and 58.9 events per 100 patient-years in the control group (rate ratio, 0.64; 95% confidence interval [CI], 0.48 to 0.85; P=0.002). The rate of first or recurrent hospitalization for heart failure was 26.9 events per 100 patient-years in the device group and 46.6 events per 100 patient-years in the control group (rate ratio, 0.59; 95% CI, 0.42

 Conclusions

Among patients with heart failure with moderate to severe functional mitral regurgitation who received medical therapy, the addition of transcatheter mitral-valve repair led to a lower rate of first or recurrent hospitalization for heart failure or cardiovascular death

Disclaimer:

Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any

Ticagrelor monotherapy in ST-elevation myocardial infarction: An individual patient-level meta-analysis from TICO and T-PASS trials

Med. 2024 Aug 10:S2666-6340(24)00301-5.

 Abstract

Background: Patients with ST-elevation myocardial infarction (STEMI) tend to be excluded or under-represented in randomized clinical trials evaluating the effects of potent P2Y12 inhibitor monotherapy after short-term dual antiplatelet therapy (DAPT).

 Methods: Individual patient data were pooled from randomized clinical trials that included ST-elevation myocardial infarction  STEMI patients undergoing drug-eluting stent (DES) implantation and compared ticagrelor monotherapy after short-term (≤3 months) short-term

 Findings: The pooled cohort contained 2,253 patients with ST-elevation myocardial infarction. The incidence of the primary efficacy outcome did not differ between the ticagrelor monotherapy group and the ticagrelor-based dual antiplatelet therapy group (1.8% versus 2.0%; hazard ratio [HR] = 0.88; 95% confidence interval [CI] = 0.49-1.61; p = 0.684). There was no difference in cardiac death between the groups (0.6% versus 0.7%; HR = 0.89; 95% CI = 0.32-2.46; p = 0.822). The incidence of the primary safety outcome was significantly lower in the ticagrelor monotherapy group (2.3% versus 4.0%;

 Conclusions: In patients with ST-elevation

Disclaimer:

Lupin makes no

Efficacy and Safety of P2Y12 monotherapy vs DAPT  in patients undergoing percutaneous coronary intervention: meta-analysis of randomized trials

Curr Probl Cardiol. 2024 Aug;49(8):102635. doi: 10.1016/j.cpcardiol.2024.102635

 Abstract

Background: Debates persist regarding the optimal duration of dual antiplatelet therapy (DAPT) after

 Methods: Multiple databases were searched. Six RCTs with a total of 24877 patients were included. The primary endpoint was all-cause mortality at 12 months of follow-up. The secondary endpoints were cardiovascular mortality, myocardial infarction, probable or definite

 Results: Monotherapy with P2Y12 inhibitor ticagrelor significantly reduced both all cause mortality (HR 0.71, 95 CI [0.55-0.91], P = 0.007) and cardiovascular mortality (HR 0.66, 95% CI [0.49-0.89], P = 0.006) compared to standard dual antiplatelet therapy  DAPT. In contrast, clopidogrel monotherapy did not demonstrate a similar reduction. The decrease in mortality associated with ticagrelor was primarily due to a lower risk of

 Conclusions: In comparison to standard dual antiplatelet therapy DAPT, P2Y12 inhibitor monotherapy with ticagrelor may lead to a reduced mortality. The clinical benefits are driven by a reduction of bleeding risk without ischemic risk trade-off.

Disclaimer:

Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any